At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Akt Inhibitor MK2206 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, and 1 other intervention for Advanced Adult Hepatocellular Carcinoma and 7 related conditions. Completed, enrolled 8 participants across 8 sites.
Detailed Summary
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IV Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedAug 2011
Primary CompletionMay 2013
Study CompletionMay 2014
TodayJul 2026
First PostedAug 30, 2011
Enrollment StartApr 1, 2011
Primary CompletionMay 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.8 years ago
Interventions
Akt Inhibitor MK2206drug
Given PO
Diagnostic Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies